Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01636362 · ClinicalTrials.gov registry record · NA

A Clinical Investigation to Evaluate Efficacy of Mepitel Ag in Partial Thickness Second Degree Burns

A NA study, sponsored by Molnlycke Health Care AB.

Completed
Registry status
NA
Development phase
45
Enrollment target

NCT01636362 is a NA study that has completed, run by Molnlycke Health Care AB. The registered enrollment target is 45 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01636362, a NA study, has completed, sponsored by Molnlycke Health Care AB.

COMPLETED
Registry status
NA
Development phase
45 participants
Enrollment target

Study Summary

Approximately 55-65 subjects from 3-6 sites suffering from a burn injury covering 1-25% Total Body Surface Area (TBSA) will be evaluated providing they fulfill all inclusion and none of the exclusion criteria and have given a signed and dated informed consent. Study site will be from 1-15%. Each subject will be followed once a week for a maximum of 3 weeks or until the burn is healed if that occurs earlier. All dressing changes will be performed at the clinic and gauze rolls will be used as secondary dressing. All dressing changes will be registered in a dressing log. All subjects will be consecutively allocated to a subject code.

Interventions

  • DEVICE Mepitel Ag

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2012-08
Est. Completion 2013-08
Phase NA

Sponsor

Molnlycke Health Care AB

20 total trials

What the Registry Record Tells You About NCT01636362

The ClinicalTrials.gov registry entry for NCT01636362 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molnlycke Health Care AB, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Mepitel Ag is the first listed.

NCT01636362 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01636362 about?

NCT01636362 is a clinical study titled "A Clinical Investigation to Evaluate Efficacy of Mepitel Ag in Partial Thickness Second Degree Burns". Approximately 55-65 subjects from 3-6 sites suffering from a burn injury covering 1-25% Total Body Surface Area (TBSA) will be evaluated providing they fulfill all inclusion and none of the exclusion criteria and have given a signed and dated informed consent. Study site will be from 1-15%. Each sub...

What is the current status of trial NCT01636362?

This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2012-08. Estimated completion is 2013-08.

What interventions are being tested in trial NCT01636362?

The interventions under investigation include: Mepitel Ag (DEVICE).

Who is sponsoring clinical trial NCT01636362?

This trial is sponsored by Molnlycke Health Care AB, which has 20 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.